John chairs the Photopharmica Board and was previously Global Vice President at Covance with a specific focus on managing the drug development process. He has a background in venture capital, audit with PricewaterhouseCoopers, management consultancy with Coopers and Lybrand Deloitte and holds a Professorship at Warwick Business School.
His initial training was as a Clinical Biochemist at St George's Hospital and St Mary's Hospital in London, and has been the Chair of several technology based companies in the UK.
Stan is a founder of the company and was responsible for the scientific R&D and the clinical development of the Company’s lead products. Stan is a recognised international authority in PDT who has published very widely on the subject. Stan has also been the University of Leeds Chair of Biochemistry and Director of the University’s Centre of Photobiology and Photodynamic Therapy. He was Pro-Vice Chancellor of the University of Leeds 1993-96, President of the European Society for Photobiology 1999-2001 and a non-executive director of Yorkshire Regional Health Authority.
Steve Felstead is Vice President, Clinical Research Head, Pharmatherapeutics Division at Pfizer. Steve is responsible for the disciplines of Clinical Development and Pharmacology, Precision Medicine, Preclinical and Clinical Statistics.
The Pharmatherapeutics Clinical Research division is responsible for research projects up to Proof of Concept (Phase 2a) in the following therapeutic areas: Neuroscience, Cardiovascular and Metabolic Disease, Anti-Infectives and Pain. From 2007-2008, Steve served as Development Therapeutic Area Head for Allergy and Respiratory medicines through to Phase 3b. Previously he held a number of project, line and administrative roles within drug development in the UK and USA, and had lead teams responsible for the successful registration of several new medicines. He joined Pfizer in 1989, having qualified in medicine at Leeds University in 1982.
Cassie joined the board of Photopharmica Ltd in January 2013. Cassie is a Business Development Manager with IP Group, a VC and leading UK intellectual property commercialisation company. Cassie has extensive experience in the commercialisation of life science technology, including company acquisitions, licensing deals, securing finance and research and clinical development. She current sits on the board of five life science companies. Cassie holds a degree and PhD in Biochemistry from the University of Leeds.
Nigel is responsible for the business and corporate development of the company. He has more than 20 years of experience in the pharma-biotech sector, with particular expertise in the commercialization of small molecules, biologics and medical devices. He established Tukan Partners in 2005 and prior to that was on the management team at Astex Therapeutics and at Cantab Pharmaceuticals. He has a PhD in Molecular Biology from Cambridge University and a BSc in Chemistry from the University of Manchester.
Clare is Senior Programme Manager at Photopharmica and responsible for the management of pre-clinical and clinical development programmes. Clare has a BSc in Biomedical Sciences and graduated with First Class Honours. She also has a PhD in anti-cancer photodynamic therapy which was undertaken in the Centre of Photobiology and Photodynamic Therapy at the University of Leeds prior to her move into industry in 2007.